Tomczak, Ewa published the artcileResolution of cryptosporidiosis in transplant recipients: review of the literature and presentation of a renal transplant patient treated with nitazoxanide, azithromycin, and rifaximin, Quality Control of 55981-09-4, the main research area is cryptosporidiosis nitazoxanide azithromycin rifaximin renal transplantation; Cryptosporidium; azithromycin; cryptosporidiosis; nitazoxanide; transplant recipient.
Background.Cryptosporidium is a major cause of diarrheal disease worldwide, including chronic disease in malnourished children and patients with acquired immune deficiency syndrome. There are increasing reports of cryptosporidiosis in transplant patients, especially from middle-income countries. Methods. The literature on treatment of cryptosporidiosis in transplant patients was reviewed and included no controlled trials but only small case series. Nitazoxanide, azithromycin, spiramycin, and combination therapies have been used, but none are consistently efficacious. Results. We present a case of chronic diarrhea from cryptosporidiosis in a renal transplant patient. His illness resolved with decreasing immunosuppression and treatment with the 3-drug combination of nitazoxanide, azithromycin, and rifaximin. Conclusions. Although current therapies are not reliably effective in the absence of an effective cellular immune response, combination therapies hold promise for improved responses.
Open Forum Infectious Diseases published new progress about Cryptosporidiosis. 55981-09-4 belongs to class esters-buliding-blocks, name is 2-((5-Nitrothiazol-2-yl)carbamoyl)phenyl acetate, and the molecular formula is C12H9N3O5S, Quality Control of 55981-09-4.
Referemce:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics